Veracyte (NASDAQ:VCYT) Price Target Raised to $48.00 at Needham & Company LLC

Veracyte (NASDAQ:VCYT) had its target price increased by Needham & Company LLC from $44.00 to $48.00 in a research note released on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

VCYT has been the subject of a number of other reports. Zacks Research upgraded shares of Veracyte from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 11th. UBS Group reiterated a “buy” rating on shares of Veracyte in a research report on Monday, January 12th. Morgan Stanley boosted their price target on shares of Veracyte from $40.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, December 1st. Canaccord Genuity Group raised their price objective on Veracyte from $40.00 to $43.00 and gave the company a “hold” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Veracyte in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Veracyte Trading Up 8.6%

Shares of Veracyte stock opened at $38.80 on Thursday. The firm has a market capitalization of $3.07 billion, a PE ratio of 46.74 and a beta of 1.91. The business’s 50-day moving average price is $39.97 and its 200-day moving average price is $37.78. Veracyte has a 12 month low of $22.61 and a 12 month high of $50.71.

Veracyte (NASDAQ:VCYT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.12. The company had revenue of $140.64 million during the quarter, compared to the consensus estimate of $135.79 million. Veracyte had a return on equity of 8.19% and a net margin of 12.83%.Veracyte’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS. As a group, analysts predict that Veracyte will post 0.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Karin Eastham sold 20,000 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $45.45, for a total value of $909,000.00. Following the completion of the transaction, the director owned 13,554 shares of the company’s stock, valued at approximately $616,029.30. This represents a 59.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Leite sold 1,278 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $47.51, for a total value of $60,717.78. Following the completion of the transaction, the insider owned 82,113 shares of the company’s stock, valued at approximately $3,901,188.63. The trade was a 1.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 54,385 shares of company stock valued at $2,483,179 over the last quarter. 1.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Veracyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VCYT. Vanguard Group Inc. raised its holdings in Veracyte by 5.0% in the third quarter. Vanguard Group Inc. now owns 8,504,088 shares of the biotechnology company’s stock worth $291,945,000 after purchasing an additional 403,737 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Veracyte by 16.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 7,370,467 shares of the biotechnology company’s stock worth $253,028,000 after acquiring an additional 1,048,692 shares in the last quarter. ARK Investment Management LLC increased its stake in shares of Veracyte by 17.5% in the 3rd quarter. ARK Investment Management LLC now owns 4,465,775 shares of the biotechnology company’s stock worth $153,310,000 after acquiring an additional 665,686 shares in the last quarter. State Street Corp lifted its position in Veracyte by 3.8% during the 4th quarter. State Street Corp now owns 4,360,913 shares of the biotechnology company’s stock valued at $183,594,000 after acquiring an additional 161,239 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Veracyte by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 3,118,166 shares of the biotechnology company’s stock worth $107,042,000 after acquiring an additional 95,664 shares in the last quarter.

Key Veracyte News

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Q4 beat — Veracyte reported Q4 revenue of about $140.6M (up ~18.5% y/y) and EPS of $0.53, topping consensus; management highlighted improved margins and a big jump in profitability versus year-ago quarter. Veracyte Q4 Earnings Beat
• Positive Sentiment: Profitability & cash improved materially — operating profit, net income and cash from operations rose substantially year-over-year and cash & equivalents increased (QuiverQuant summary), supporting a stronger financial profile. QuiverQuant Financial Snapshot
• Positive Sentiment: 2026 guidance and product cadence — management outlined 2026 revenue growth of 10%–13% and plans to advance MRD efforts and Prosigna launches, giving investors visibility on growth drivers beyond core testing. Veracyte 2026 Outlook
• Positive Sentiment: Analyst upgrade/price-target lift — Needham bumped its price target (to $48) and maintains a Buy, adding upside from current levels and likely helping investor sentiment. Benzinga Analyst Note
• Neutral Sentiment: Full earnings materials & call transcripts available — management commentary and the earnings deck/transcript provide detail on revenue mix and pipeline; useful for modeling but not a surprise after the print. Earnings Call Transcript
• Negative Sentiment: Insider selling and mixed institutional flows — recent data show substantial insider sell activity and large institutional position changes (some big sellers), which could temper enthusiasm despite the beat. QuiverQuant Insider & Institutional Activity

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.